Virax Biolabs announced an exclusive multi-country supply agreement with Fosun Diagnostics to ship ImmuneSelect RUO products across six Southeast Asian markets, including Thailand and Malaysia. The deal creates near-term revenue visibility via purchase orders and leverages Fosun's regional network for rapid expansion, with initial TB-related applications in Thailand and potential OEM/private-label opportunities.
Virax Biolabs has obtained ISO 13485 and ISO 9001 certifications, enhancing its quality management systems. These certifications are crucial for advancing its diagnostics focused on post-acute infection syndromes, particularly Long COVID, supporting both clinical validation and potential U.S. market offerings.
H.C. Wainwright initiated coverage on VRAX with a Buy rating. The company is developing a T cell-based immunology profiling platform. VRAX estimates 254,000-301,000 patients could benefit annually from its technology. A diagnostics market for long COVID could be worth hundreds of millions. Clinical study data on VRAX’s technology expected by Q2 2026.
